BREAKING
Q32 Bio Inc. (QTTB) Reports Q4 Earnings 52 seconds ago BioNTech (BNTX) Posts Q4 Loss of $-1.25/Share as Revenue Falls 23.8% YoY to $907.4M 7 minutes ago Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year 12 minutes ago Tenax Therapeutics Inc (TENX) Reports Q4 Earnings 14 minutes ago Opus Genetics Inc. (IRD) Reports FY25 Earnings 18 minutes ago Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share 24 minutes ago Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings 30 minutes ago Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates 37 minutes ago Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M 41 minutes ago Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M 44 minutes ago Q32 Bio Inc. (QTTB) Reports Q4 Earnings 52 seconds ago BioNTech (BNTX) Posts Q4 Loss of $-1.25/Share as Revenue Falls 23.8% YoY to $907.4M 7 minutes ago Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year 12 minutes ago Tenax Therapeutics Inc (TENX) Reports Q4 Earnings 14 minutes ago Opus Genetics Inc. (IRD) Reports FY25 Earnings 18 minutes ago Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share 24 minutes ago Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings 30 minutes ago Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates 37 minutes ago Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M 41 minutes ago Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M 44 minutes ago
ADVERTISEMENT
Breaking News

Yalla Group (YALA) Reports Q4 EPS of $0.20 as Revenue Stalls at $83.9M

Yalla Group reports Q4 adjusted EPS of $0.21 on flat sequential revenue of $83.9M, maintaining profitability but showing zero growth.

$YALA March 10, 2026 2 min read
NYSE
$YALA · Earnings

Yalla Group reports Q4 adjusted EPS of $0.21 on flat sequential revenue of $83.9M, maintaining profitability but showing zero growth.

Earnings Per Share (adj.)
$0.20
estimate N/A
Revenue
$83.9M
estimate N/A

Flat quarter for Yalla. Yalla Group Limited (NYSE: YALA) reported adjusted EPS of $0.20 for Q4 2025, matching the prior quarter’s $0.21 result. No consensus estimate was available for comparison. The software company generated adjusted net income of $36.9 million on revenue of $83.9 million for the quarter ended December 31, 2025.

Revenue stalls sequentially. Q4 revenue of $83.9 million came in flat versus the prior quarter’s $83.9 million, signaling zero sequential growth for the Middle East-focused social networking and gaming platform. Gross profit reached $57.6 million on cost of revenue of $26.3 million, yielding a gross margin of 68.7%. Operating income totaled $26.6 million for the quarter.

Profitability holds steady. The company maintained its profitability profile with GAAP diluted EPS of $0.20 and GAAP net income of $34.5 million. Shares traded at $7.04 with volume of 211,400 shares, giving the company a market capitalization of $1.11 billion. The stock remains well below its 52-week high of $9.29 but significantly above the $3.96 low.

What to Watch: The earnings call scheduled for 8:00 PM ET on March 10, 2026 will be critical for understanding whether the sequential revenue stall reflects seasonal headwinds or deeper user engagement challenges in Yalla’s core Middle East markets. Management’s Q1 2026 guidance will signal whether growth can reaccelerate.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

ADVERTISEMENT
Tags: #YALA